Two observations underlie the hypothesis upon which this study was undertaken. The first is that IgA is the predominant class of immunoglobulins in bronchial secretions (Keimowitz, 1964) . Externallysecreted IgA and, to a lesser extent, serum IgA participate in the immunological response to respiratory infection (Rossen, Butler, Waldman, Alford, Hornick, Togo, and Kasel, 1970; Smith, Bellanti, and Chanock, 1967) and it has been suggested that IgA may play a role in regulating the normal bacterial and viral flora of external membranes (Tomasi, 1968) . The second observation is that one stimulus to rheumatoid factor production may be IgG antibody complexed to antigen (Henney, 1969) . Rheumatoid factors occur in a variety of acute and chronic infections (Bartfeld, 1969) and their titres fall when the antigenic stimuli are removed (Williams and Kunkel, 1962) . Thus, the relationship between IgA and pulmonary defence mechanisms combined with the knowledge that chronic antigenic stimulus may lead to production of anti-antibodies prompted speculation that, if a chronic antigenic stimulus is present in some pulmonary diseases, antibody against IgA might be found in patients with these diseases.
This study presents a survey of patients with chronic pulmonary disease and of control groups for the presence of anti-IgA antibodies. Patients were also studied for anti-IgG antibodies (rheumatoid factor) and cryoprecipitates. The results show that antibodies to IgA and cryoprecipitates occur with relative frequency in the sera of patients who have rheumatic or immunological disease when chronic pulmonary disease is associated. Anti-IgA antibodies do not occur in blood donors, other hospitalized patients (one exception noted below), patients with pulmonary disease not associated with underlying rheumatic or immunological disease, or patients with rheumatic disease but without demonstrable pulmonary disease.
Methods

MONOCLONAL PROTEIN PREPARATION
Monoclonal proteins were obtained from patients with multiple myeloma. Separation of IgA from the other immunoglobulins was facilitated by having a patient whose IgA peak migrated in the alpha2 region on serum protein electrophoresis. Whole serum was subjected to starch block electrophoresis. The starch block eluates were vacuum concentrated, dialysed against 0-02 M phosphate buffer at pH 8, and purified by DEAE-cellulose column chromatography. IgG was eluted from the column with 0-02 M phosphate buffer at pH 8 and IgA was then eluted with 0-15 M phosphate buffer at pH 6-8. Purity of the monoclonal proteins was demonstrated by immunoelectrophoresis against anti-whole serum and monospecific antisera (Hyland) and by radial immunodiffusion (Mancini, Carbonara, and Heremans, 1965) .
LATEX-FIXATION TEST
This was performed by the method of Singer and Plotz (1956) . Latex particles, mean diameter 0-81 I,u were employed (Kallestad). Whole serum was heat-inactivated at 56°C. for 30 min and incubated with latex particles at 56°C. for 2 hrs. Serial dilutions from 1: 5 to 1: 5,120 were tested. Agglutination of 2+ or greater in a dilution of 1: 40 or greater was graded positive and 1+ agglutination or no agglutination was graded negative. Known positive and negative control sera were tested simultaneously with each group of test sera. Test sera did not agglutinate uncoated latex particles. Anti-IgG antibody activity was detected by coating the latex particles with commercially prepared human Fraction II (Hyland) in the screening studies and with Fraction II or monoclonal IgG in the adsorption and inhibition studies. Anti-IgA antibody activity was detected by coating latex particles with monoclonal IgA. Rabbit and goat anti-human-IgA anti-sera agglutinated latex particles coated with the monoclonal IgA and did not agglutinate uncoated, IgG-coated, or Fraction II-coated latex particles. sample was then centrifuged at 2,000 r.p.m. for 10 min. and the serum was separated immediately. Serum was allowed to stand at 4°C. for 72 hrs, during which time it was observed at daily intervals for the presence ofprecipitation. Cryoprecipitates were separated by spinning sera at 15,000 r.p.m. in a Servall centrifuge at 4°C. for 30 min. and were purified by multiple re-suspensions at 37°C. and re-precipitations at 4°C. in phosphate-buffered saline pH 7-4. The purified cryoprecipitates were re-suspended in phosphate-buffered saline at 37°C. and the immunoglobulin content was determined by immunoelectrophoresis against antiwhole serum and monospecific antisera. Antibody activity in the cryoprecipitates was determined by the latex test.
IMMUNOADSORPTION
Monoclonal IgG and IgA were insolubilized by crosslinkage to glutaraldehyde and antibody was adsorbed from the sera by the method of Avrameas and Ternynck (1969) . The amount of insolubilized protein used as immunoadsorbant was 100 mg. and elution of adsorbed protein was accomplished with 0-1 M glycine-HCl solution pH 2-8. Each serum (0-8 ml.) was adsorbed with insolubilized IgG and IgA by this method six times. The unadsorbed serum and the adsorbed serum were then tested simultaneously for anti-IgA and anti-IgG activity by the latex-fixation test.
INHIBITION STUDIES
An inhibition experiment, also employing the latex test, was designed. Each test serum was diluted so that it contained enough antibody activity to give 2+ agglutination of the latex particles at that and two higher dilutions, but not enough activity to agglutinate them at three higher dilutions. Diluted serum (0-125 ml.) was added to an equal volume of01 M glycine-NaCI solution pH8-2containing0, 0-062,0-125,0-25, or0-5 mg. inhibitor(FII, monoclonalIgG or monoclonal IgA). The serum with inhibitor was then added to 0-25 ml. latex suspension, the particles of which were coated with FIT, monoclonal IgG, or monoclonal IgA. Two monoclonal IgG (one kappa type and one lambda type) and two monoclonal IgA (both kappa type, designated K1 and K2) proteins were employed.
SEPARATION STUDIES
For sucrose density gradient separations, sera were diluted 1:1 with phosphate-buffered saline pH 7.4, and 0 3 ml. was layered over a 10 to 40 per cent. sucrose gradient and centrifuged at 35,000 r.p.m. for 18 hrs in a Beckman model L-2 preparative ultra-centrifuge with an SL-50.1 rotor. Gradient fractions were collected from the bottom and assayed for total protein content. 19S and 7S fractions were pooled, and anti-IgA and anti-IgG activity determined by the latex fixation test.
Sephadex G-200 column separations were performed on 80 x 1-5 cm. columns equilibrated with 0.1 M acetate buffer pH 3 0. Whole serum (2 ml.) dialysed to pH 3 0 was employed. Each fraction was assayed for total protein content. Peak fractions were pooled and vacuum concentrated in collodion bags. Immunoglobulin content was determined by immunoelectrophoresis and anti-gammaglobulin activity was determined by the latex fixation test.
OTHER PROCEDURES
Serum immunoglobulin levels were measured by the radial immunodiffusion method (Mancini and others, 1965) .
Haemolytic complement was determined in the immunochemistry laboratory of the University of Minnesota Hospitals by standard methods (Pickering, Gewurz, and Good, 1968) .
Subjects
Three groups were studied: (1) 57 patients who had infectious and non-infectious pulmonary diseases. In most of them the pulmonary disease was primary but in a few it was associated with rheumatic or immunological disease.
(2) 52 patients with rheumatic diseases, largely rheumatoid arthritis (R.A.) and systemic lupus erythematosus (S.L.E.), but without pulmonary involvement as determined by history, examination, chest roentgenograms and, in most cases, spirometry. (3) 75 presumably healthy blood donors and 81 consecutively hospitalized patients.
Each patient with R.A. had a diagnosis of definite or classical disease by the criteria of the American Rheumatism Association (Committee of the A.R. A., 1964) . Each patient with the diagnosis of S.L.E. had documented multisystem disease, a positive bead defibrination test for L.E. cells and anti-DNA antibody in the serum. A diagnosis of interstitial pulmonary disease (I.P.D.) was based on history, examination, chest roentgenogram, pulmonary function studies, and autopsy (1 patient). All pulmonary function tests shown (Table II) were done after the patients had recovered from acute illness.
Results
SCREENING STUDIES
Eleven patients in Group 1 had anti-IgA antibody in their sera (Table I ). The clinical diagnosis of these patients were: mixed cryoglobulinaemia with recurrent pulmonary infections (1); sicca syndrome with recurrent acute and chronic pulmonary infections (1); rheumatoid arthritis with I.P.D. and recurrent and/or chronic pulmonary infections (3); rheumatoid arthritis and I.P.D. (1); rheumatoid arthritis, chronic bronchitis, and bronchiectasis (1) (Vyas, Holmdahl, Perkins, and Fudenberg, 1969) , the relationship of the anti-IgA antibody to her underlying disease is uncertain. Two other patients with alcoholic cirrhosis were included among the hospitalized control patients and neither had anti-IgA antibody in his serum.
SEROLOGICAL STUDIES
Serological abnormalities in the eleven patients with pulmonary disease and anti-IgA antibody are shown in Table III (overleaf) . Each patient with anti-IgA antibody also had anti-IgG antibody in his serum. The sera from eight of the eleven patients contained cryoprecipitates. All eight cryoprecipitates 4 contained IgG and seven of the eight cryoprecipitates were mixtures of immunoglobulins. Four contained IgM and IgG; each of these had high-titre anti-IgG activity and no anti-IgA (1, 3, and 11) or low-titre anti-IgA (2) activity. Two cryoprecipitates contained IgG and IgA (4 and 9) and one contained IgM, IgG, and IgA (7) The results are shown in Table VII (overleaf). AntiIgG activity was demonstrated in the 19S fraction by sucrose density gradient separation in three patients (7, 10, and 6) and in both 19S and 7S fractions in two (9 and 5). Anti-IgA activity was found in the 19S fraction in one patient (7) 
IgA(K2)
TgA ( been found to have antibodies to whole human IgA present in their sera. Nine of these patients had definite associated rheumatic or immunological disease: mixed cryoglobulinaemia, rheumatoid arthritis, undefined polyarthritis, S.L.E., and the sicca syndrome. In addition, the P.I.E. syndrome (1 patient) may be a manifestation of an underlying immunological disorder (Hall, Kozak, and Spink, 1964 but without bacteriological confirmation in two patients (8 and 6). Two patients (5 and 9) did not have infections; both had I.P.D., one associated with rheumatoid arthritis and one with P.I.E. syndrome. The relationship of the P.I.E. syndrome to the I.P.D. is uncertain in Patient 9, but it has been noted that the former may progress to the latter (Carrington, Addington, Goff, Madoff, Marks, Schwaber, and Gaensler, 1969) . The incidence of anti-IgA antibody among patients with rheumatic or immunological disease and associated pulmonary disease is high in this sample of patients. Conversely, the incidence of this antibody among patients with infectious and non-infectious pulmonary disease without associated rheumatic disease is low or absent depending on how one classifies the P.I.E. syndrome, and with the exception of the patient with chronic bronchitis and I.P.D. Anti-IgA antibody was not found in a blood donor population or in hospitalized patients with one exception noted under Results. The anti-IgA antibody was also not found in 52 patients with rheumatic and immunological disease who had no clinically demonstrable pulmonary involvement. These preliminary observations suggest that the anti-IgA antibody may mark a small subgroup of patients with rheumatic and immunological disease that has a diathesis for development of pulmonary disease.
Regarding the separate identity of the anti-IgA and anti-IgG antibodies, the results of the adsorption experiments in all eleven patients support entirely the hypothesis that two separate antibodies or groups of antibodies account for the anti-IgA and anti-IgG activity in these sera. Adsorption of antibody activity from these sera with monoclonal IgA and IgG as immunoadsorbants resulted in selective decrease in, respectively, anti-IgA and anti-IgG titres by two to four tube dilutions. No cross-adsorption was found. Why the adsorption procedure did not decrease antibody titres to zero is uncertain, but certainly not all the insolubilized monoclonal protein which was divided into relatively coarse particles was available for interaction with anti-antibody. Further, insolubilization with glutaraldehyde may not best alter the monoclonal protein to make available the antigenic sites with which these antibodies interact.
The results of the inhibition experiments also support the hypothesis that two separate antibodies account for anti-IgA and anti-IgG activity. In six patients inhibition experiments with FII, monoclonal IgG and monoclonal IgA demonstrated complete separation of antibody activity. In the remaining four patients overlap inhibition (inhibition of FIl or IgGcoated latex agglutination by IgA or the converse) occurred at the highest inhibitor concentration employed. However, it should be noted that the overlap occurred in only one of three experiments in Patient 9 and one of two experiments in Patients 7, 3, and 10. In the other experiments in these patients complete separation of antibody activity was demonstrated and good separation of antibody activity was also achieved with the adsorption experiments in each of these patients. The reason for the overlap is not known but may represent a nonspecific inhibition effect at the higher protein concentration or measurement of genetic factor or subgroup.
Antibody characterization experiments demonstrated the class of antibody containing the anti-IgA activity to be in the 7S fraction in four of five sera, and also provided further evidence of separation from anti-IgG activity which was in the 19S, IgM fraction only in three of the five sera. We have no information to date relating to the site at which IgA and anti-IgA antibodies interact or to the possible subtype specificities of the anti-IgA antibodies.
A pathogenic relationship between the anti-IgA antibody and the pulmonary disease is speculative. This study was undertaken in part because of the observation that in humans chronic antigenic stimulation may lead to rheumatoid factor formation. In animals there is experimental evidence that antigammaglobulin factors can be produced by administration of altered autologous gammaglobulin (Milgrom and Witebsky, 1960) or autologous gammaglobulin complexed to antigen (Williams and Kunkel, 1963) . The observation in this study that anti-IgA antibodies do not occur in patients with primary infectious pulmonary diseases argues against a chronic antigenic stimulus as origin for the anti-IgA antibody. However, there is no way to rule out the possibility that the patients with rheumatic diseases and anti-IgA antibody in the serum have a diathesis that allows locally-produced IgA complexed to antigen to be exposed to systemic antibody-producing mechanisms, while patients without this diathesis are able to contain or destroy complexed IgA locally. It has been postulated that rheumatoid factor as a part of immune complexes may precipitate in vivo in pulmonary capillaries (Tomasi, Fudenberg, and Finby, 1962) , possibly leading to inflammation and fibrosis (Cochrane, 1968) . Deposition of immunoglobulins in alveolar septa of some patients with idiopathic I.P.D. has been demonstrated (Nagaya, Buckley, and Sieker, 1969) . In the absence of biopsy material, there is no direct evidence from patients in this study to support a pathogenic role for immune complexes. However, in three patients, there was clinical evidence (presence of renal disease and lowered serum complement in all and demonstration of glomerular immunoglobulin deposition on renal biopsy in one) of renal immune-complex deposition and one might speculate that such deposition could occur in the pulmonary vasculature as well. The finding of cryoprecipitates in eight of eleven patients in this study is also ofinterest in this regard. However, there was no clinical evidence of renal disease in the other patients with anti-IgA antibody.
Previous studies have noted antibodies to human IgA in patients with IgA deficiency and patients with transfusion reactions, apparently due to exposure to or administration of incompatible IgA (Fudenberg, Gold, Vyas, and Mackenzie, 1968; Vyas and others, 1969; Ammann and Hong, 1971) . In contrast, the patients in this study had not been transfused and had generally high levels of serum IgA; we do not know if they were deficient in an IgA subgroup. Human antibodies to IgA fragments have also been studied but their clinical significance remains to be established (Wilson, Soltis, and Williams, 1970) . It is clear from this survey that anti-IgA antibody also occurs in a subgroup of patients with rheumatic diseases, namely those with I.P.D. and chronic or recurrent pulmonary infections. Anti-IgA antibody may eventually provide a unifying concept for pulmonary disease occurring in association with an otherwise apparently heterogenous group ofrheumatic diseases.
Summary
Eleven patients with pulmonary disease, ten of whom had associated rheumatic or immunological disease, had antibodies to IgA in their sera. All also had antiIgG antibody and eight had cryoglobulins. All cryoglobulins contained anti-IgG antibody and five contained anti-IgA antibody. Adsorption and inhibition experiments demonstrated separation ofanti-IgG and anti-IgA activity. Anti-IgA activity was found mainly in the 7S fraction, and anti-IgG activity, mainly in the 19S, IgM fraction. 
